Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07178353

Human Skeletal Muscle Response to 5 Days of Bedrest in Young Adults

The goal of this intervention trial is to characterize skeletal muscle atrophy in healthy, young adults during short term bedrest. The main questions it aims to answer are:

How much do skeletal muscle volume, strength, and fatigue resistance decline during bedrest? How much does whole-body insulin sensitivity change during bedrest? How do mitochondrial function and protein synthesis change during bedrest?

Participants will undergo the following tests before and after a free-living control period and before and after a 5 day period of strict horizontal bedrest:

* Magnetic resonance imaging of the thigh muscles * Strength testing of the thigh muscles * Insulin sensitivity testing in response to a mixed meal * Exogenous glucose oxidation in response to a mixed meal * Muscle biopsies from the thigh muscles * Blood samples

Recruiting

Interested in participating?

Request Info

Key information

About this study

Skeletal muscle plays a critical role in physical function and metabolic health, with its maintenance driven by the balance between muscle protein synthesis (MPS) and muscle protein breakdown (MPB). During periods of disuse, such as illness or injury, MPS declines while MPB remains relatively unchanged, leading to muscle loss and atrophy. Short-term disuse, such as bedrest, is commonly experienced through hospitalization, and can result in rapid declines in muscle mass and strength, typically affecting the lower limbs to a greater extent. At the molecular level, bed rest significantly reduces MPS, with durations as little as 3 days showing drastic impairment in skeletal muscle turnover. Additionally, short-term periods of disuse have shown to blunt mitochondrial respiration, affecting the ability for skeletal muscle to produce energy for proper funcitoning and metabolic processes. Diminished skeletal muscle metabolic function directly impacts whole-body metabolic health. Periods of bedrest between 5 and 7 days have shown to decrease whole-body glucose tolerance, increase insulin resistance, and decrease insulin-stimulated leg glucose uptake. All together, these contribute to decreased skeletal muscle mass and strength, and diminished metabolic function, contributing to a decline in overall physical function, health, and well-being. Current studies on short-term bed rest (ex. 5 days) in young adults are limited, and existing research has focused on simulated microgravity models rather than horizontal bed rest, which better represents clinical scenarios. Additionally, no study to our knowledge has explored how the molecular mechanisms that drive MPS change over the course of a 5-day bedrest period. This highlights a need to explore if there are differences in the attrition of synthesis rates of the different protein pools in skeletal muscle (ex. myofibrillar, sarcoplasmic, and mitochondrial).

The purpose of the present study is to investigate changes in leg muscle mass, strength, and whole-body insulin sensitivity over five days of bed rest, as well as examine the time-course changes in molecular mechanisms underlying skeletal muscle turnover. The investigators hypothesize that, compared to the control period, quadriceps muscle size (volume and cross-sectional area), strength/power/fatigue resistance, and whole-body insulin sensitivity will decrease following bedrest. The investigators hypothesize that these outcomes will be linked to decreases in mitochondrial respiratory function and impaired fractional synthetic rates of muscle proteins.

In this repeated-measures design, participants will undergo a five day baseline control period followed by five days of bed rest to compare changes from bedrest to their own free-living control period.

Findings from this study will help inform future research on the impact of short-term, clinically-relevant, bedrest in young adults and aid in the development of targeted interventions to mitigate declines in muscle mass from occurring from acute bouts of muscle disuse.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females 18-30 years
  • BMI between 18.5-28 kg/m2
  • Weight stable (within ±2kg for 6 months)
  • Generally healthy as assessed by medical and physical activity questionnaires
  • recreationally active

Exclusion criteria

  • a BMI < 18.5 and > 28 kg/m2
  • the use of insulin to control blood glucose levels
  • a history of any cardiovascular, respiratory, metabolic diseases, neuromuscular or bone-wasting diseases
  • the use of any medication that may affect muscle protein turnover (e.g. androgen or anabolic hormone therapy, chemotherapy)
  • a (family) history of thrombosis, platelet or coagulation disorders, or antiplatelet therapy and the use of anticoagulant medications
  • the presence of any unremoved, or partially removed metals underneath the skin
  • a history of head or eye injury involving metal fragments
  • have some type of implanted electrical device (such as a cardiac pacemaker or neurostimulator)
  • have implanted metal objects as a result of surgery, such as artificial joints, aneurysm clips, metal staples
  • are, or may be, pregnant
  • are wearing metal braces on their teeth.

Treatment and study plan

Bedrest

Other

5 days of strict bedrest. Participants are allowed to sit up in bed, but will perform any bathing or bathroom activities in a wheelchair.

Other names: Horizontal Bedrest

Primary outcomes

  1. Quadriceps muscle volume

    Time frame: Day 0, and 5

    Quadriceps muscle volume will be assessed by magnetic resonance imaging.

Secondary outcomes

  1. Muscle strength

    Time frame: Day -14, -9, and 5

    Knee extensor peak torque will be assessed using dynamometry

  2. Knee extensor power

    Time frame: Day -14, -9, and 5

    Peak isotonic power determined at 30% maximal isometric voluntary contraction torque using a dynamometer

  3. Muscle fatiguability

    Time frame: Day -14, -9, and 5

    Knee extensor fatiguability will be determined by the decrease in isotonic power across 40 contractions at 30% MVC using dynamometry.

  4. Muscle cross-sectional area

    Time frame: Day 0 and 5

    Change in quadriceps muscle cross sectional area measured by magnetic resonance imaging scan.

  5. Muscle protein synthesis

    Time frame: Day -5 to 0, day 0 to 1, day 0 to 3, day 0 to 5, day 1 to 3, day 1 to 5, and day 3 to 5.

    Muscle protein synthesis measured as fractional synthesis rate of the myofibrillar, sarcoplasmic, and mitochondrial protein pools within skeletal muscle. These 3 pools will be assessed using combined protocol of skeletal muscle biopsy, stable isotope tracing, cavity ring down spectroscopy with liquid isotope analysis, and gas-chromatography pyrolysis isotope-ratio mass spectrometry.

  6. 2-hour plasma glucose incremental area under the curve

    Time frame: Aggregate 2-hour window on day -5, 0, and 5

    Determination of the total rise in plasma glucose during a mixed meal tolerance test, to be assessed by an enzyme-linked immunosorbent assay.

  7. 2- hour plasma insulin incremental area under the curve

    Time frame: Aggregate 2-hours on day -5, 0, and 5

    Determination of the total rise in plasma insulin during a mixed meal tolerance test, to be assessed by an enzyme-linked immunosorbent assay.

  8. Postprandial glucose oxidation

    Time frame: Aggregate 3 hours during the mixed meal tolerance test on day -5, 0, and 5

    Measurement of 13C excretion in breath samples using isotope ratio mass spectrometry.

  9. Matsuda Index

    Time frame: 2-hours on day -5, 0, and 5

    Insulin sensitivity measured via the Matsuda Index during a mixed meal tolerance test. Matsuda index values <4.0 indicate insulin resistance, with higher values representing insulin sensitivity.

  10. Mitochondrial Respiratory Function

    Time frame: Day -5, 1, 3, and 5

    Mitochondrial respiration will be assessed using an Oroboros Oxygraph 2000.

  11. Expression of Translational Factors Related to Skeletal Muscle Protein Synthesis

    Time frame: Day 0, 1, 3, and 5

    Activation of translational factors involved in skeletal muscle protein synthesis assessed by western blotting.

  12. Plasma glucose concentration

    Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5

    Plasma glucose concentration measured during a mixed meal tolerance test.

  13. Serum insulin concentration

    Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5

    Serum insulin concentration measured during a mixed meal tolerance test

  14. Peak glucose concentration

    Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5

    Peak glucose concentration measured during a mixed meal tolerance test

  15. Peak insulin concentration

    Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5

    Peak insulin concentration measured during a mixed meal tolerance test.

  16. Transmission Electron Microscopy Analysis

    Time frame: Day 0, 1, 3, and 5

    Imaging of subsarcolemmal and intermyofibrillar mitochondria to assess change in mitochondrial content from bedrest.

  17. Supine to Stand Test

    Time frame: Day 0, 5

    Orthostatic blood pressure assessment pre and post bedrest, and following recovery after bedrest

  18. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    Time frame: Day -5, 0, and 5

    Insulin resistance assessed using fasting insulin and glucose levels. Values <1.0 indicate insulin sensitivity, >1.9 and < 2.9 indicates early insulin resistance, and values >2.9 indicate significant insulin resistance

Study contacts

Contact information is provided by the study sponsor or research team.

Chris McGlory, PhD.

CONTACT

[email protected]

6135336000 ext. 75410

Sponsors and collaborators

Lead sponsor

Queen's University

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)

Registry information

Official study title

Changes in Muscle Mass, Strength, and Muscle Protein Synthesis in Response to 5 Days of Bedrest in Young, Healthy Adults

Acronym: FABRIC

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Sep 17, 2025
Registry last updated
Sep 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.